(-)-Epigallocatechin Gallate(EGCG)是多酚类黄酮抗氧化剂,能抑制端粒酶和DNA甲基转移酶,还能阻断EGF和HER-2的受体活性。
(-)-Epigallocatechin Gallate (EGCG) is a strong polyphenol catechin antioxidant found in green tea, reported to have broad efficacy against many conditions generated from oxidative damage. Also a DNMT1 inhibitor. Extensive oxidation of low density lipoproteins is correlated to cardiovascular diseases, and EGCG is reported to strongly inhibit Cu(2+)-mediated oxidative modification of LDLs. The antiapoptotic proteins Bcl-2 and Bcl-x(L) are observed to suppress apoptosis and convey survival to heavily damaged and mutated cells in vitro, and EGCG (along with the other catechins) is shown to directly inhibit these proteins, reestablishing the normal apoptotic pathway in the cell. EGCG also inhibits NOS2. Reduces Aβ42-induced cell death in three different cell types. Also inhibits β-secretase (IC50 = 1.6 μM) and glutamate dehydrogenase GDH. Inhibits cell growth and selectively induces apoptosis in A431 and human pancreatic cancer cells.
Cells[1]
The SW780 cells were cultured in Dulbecco’smodified Eagle’s medium (DMEM) containing 10% (v/v) fetal bovine serum and 1%penicillin–streptomycin at 37°C in 5% CO2 humidified incubator.
Cellviability assay
Cells (1×104/well) were seededin 96-well plates and incubated with different concentrations of EGCG for 24and 48 h. Following incubation, 30μl of MTT solution [5 mg/ml inphosphate-buffered saline (PBS)] was added to each well, and the plate was incubatedat 37°C for another 4 h. Then, the medium was discarded and150μl of DMSO wasadded to dissolve the formazan crystals. The absorbance of each sample was readat 540 nm using a microplate reader.
Animal experiments[2]
Male Wistar rats (six weeks old), with anaverage weight of 160 g, were housed at a constant temperature (23 ± 1 oC)with a12 h light-dark cycle in stainless steel wire-bottomed cages, and fed acommercial rodent chow (CE-2) and tap water ad libitum. The rats were fastedovernight and assigned to treatment groups (4–6 rats per group). (-)-EpigallocatechinGallate (EGCg) dissolved in distilled water or vehicle was administered orallyto rats at a dose of 500 mg/kg. The plasma EGCg concentration peaked at 60–120min after administration, therefore the rats were anesthetized withpentobarbital90 min after administration and exsanguinated from the abdominalaorta with a heparinized syringe to obtain the blood. In a separate experiment,rats were orally administered 100, 250, 500 mg/kg EGCg, or vehicle, and werethen anesthetized and exsanguinated as described above to analyze the ascorbicacid concentrations in plasma, lymphocytes, and adrenal glands.
Assayof antioxidant activity
The ORAC assay was carried out. In brief,50μL of sample was mixed with 150μL of 19.6nmol/L fluorescein solutions in a 96-well microplate and incubated at 37oCfor 10 min, and then 50μL of 20mM AAPH solution was added to initiate the reaction. Trolox wasused as a control standard. The fluorescence intensity at 490nm (excitation)/530nm(emission) was measured every 2 min for 2 h at 37oC using amicroplate fluorescence reader. The FRAP assay was performed. In brief, 40μLof sample was mixed with 1.2 mL of working FRAP solution in a test tube. At 4min after sample-reagent mixing, the absorbance at 593nm was measured against areagent blank at 37 oC using a UV-1600 spectrophotometer.
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Luo KW, Wei C, Lung WY, et al. EGCG inhibited bladder cancer SW780 cell proliferation and migration both in vitro and in vivo via down-regulation of NF-kappaB and MMP-9. J Nutr Biochem. 2017;41:56-64.
[2] Yokotani K, Umegaki K. Evaluation of plasma antioxidant activity in rats given excess EGCg with reference to endogenous antioxidants concentrations and assay methods. Free Radic Res. 2017;51(2):193-199.
[3] Shankar et al (2008) EGCG inhibits growth, invasion, angiogenesis and metastastasis of pancreatic cancer. Front.Biosci. 13 440.
[4] Lee et al (2005) Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol.Pharmacol. 68 1018.
[5] Ahmad et al (2000) Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor κB in cancer cells versus normal cells. Ach.Biochem.Biophys. 376 338.
分子式 C22H18O11 |
分子量 458.37 |
CAS号 989-51-5 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO >20 mg/mL |
Water >5 mg/mL |
Ethanol >20 mg/mL |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT00951834 | Alzheimer's Disease | Drug: Epigallocatechin-Gallate|Drug: Placebo | Charite University, Berlin, Germany | Phase 2|Phase 3 | 2009-10-01 | 2016-01-20 |
NCT01357681 | Huntington Disease | Drug: (2)-epigallocatechin-3-gallate (EGCG)|Drug: Placebo | Charite University, Berlin, Germany | Phase 2 | 2011-09-01 | 2015-06-15 |
NCT01744587 | NPC | Other: Epigallocatechin Gallate (EGCG)|Dietary Supplement: Placebo | National Health Research Institutes, Taiwan|Mackay Memorial Hospital|Taichung Veterans General Hospital|National Cheng-Kung University Hospital|Chang Gung Memorial Hospital|China Medical University Hospital|National Taiwan University Hospital | Phase 2|Phase 3 | 2013-04-01 | 2016-11-08 |
NCT00942422 | Multiple Myeloma and Plasma Cell Neoplasm|Precancerous Condition | Dietary Supplement: defined green tea catechin extract|Genetic: gene expression analysis|Genetic: protein analysis|Other: laboratory biomarker analysis | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) | Phase 2 | 2009-11-01 | 2015-03-18 |
NCT02008721 | Multiple System Atrophy | Drug: EGCG as putative neuroprotective agent|Drug: Placebo | Dr. Johannes Levin|German Center for Neurodegenerative Diseases (DZNE)|Deutsche Parkinson Vereinigung|Deutsche Stiftung Neurologie|ParkinsonFonds Deutschland gGmbH|Ludwig-Maximilians - University of Munich | Phase 3 | 2014-01-01 | 2016-12-28 |
NCT00459407 | Adenocarcinoma of the Prostate|Stage I Prostate Cancer|Stage II Prostate Cancer | Dietary Supplement: defined green tea catechin extract|Drug: placebo|Other: immunohistochemistry staining method|Other: immunoenzyme technique|Other: laboratory biomarker analysis|Procedure: biopsy|Other: mass spectrometry|Other: high performance liquid chromatography | National Cancer Institute (NCI) | Phase 1 | 2007-03-01 | 2014-10-07 |
NCT00303823 | Cervical Cancer|Cervical Intraepithelial Neoplasia Grade 1|Human Papilloma Virus Infection | Drug: placebo|Dietary Supplement: defined green tea catechin extract|Other: laboratory biomarker analysis | National Cancer Institute (NCI) | Phase 2 | 2005-09-01 | 2015-04-14 |
NCT00799890 | Multiple Sclerosis | Drug: Sunphenon EGCG|Drug: Placebo | Charite University, Berlin, Germany|TAIYO EUROPE | Phase 2|Phase 3 | 2009-05-01 | 2016-03-21 |
NCT01511263 | Primary Amyloidosis of Light Chain Type | Drug: Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias)|Drug: Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG | IRCCS Policlinico S. Matteo | Phase 2 | 2012-01-01 | 2016-02-24 |
NCT00134381 | Healthy | Drug: Green Tea | Rutgers, The State University of New Jersey|Rutgers University | Phase 2 | 2003-05-01 | 2015-02-02 |
NCT00573885 | Lung Cancer|Tobacco Use Disorder | Drug: defined green tea catechin extract|Other: placebo | British Columbia Cancer Agency|National Cancer Institute (NCI)|University of Cincinnati | Phase 2 | 2008-01-01 | 2012-03-07 |
NCT00611650 | Lung Cancer|Precancerous Condition|Tobacco Use Disorder | Drug: defined green tea catechin extract|Other: placebo | British Columbia Cancer Agency|National Cancer Institute (NCI)|University of Cincinnati | Phase 2 | 2006-10-01 | 2012-03-07 |
NCT01993966 | Urothelial Carcinoma | National Taiwan University Hospital | 2014-01-01 | 2013-11-19 | ||
NCT00596011 | Prostatic Hyperplasia | Drug: Polyphenon E|Drug: Placebo | H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI) | Phase 2 | 2007-12-01 | 2016-11-15 |
NCT00253643 | Precancerous Condition|Prostate Cancer | Dietary Supplement: green tea catechin extract|Dietary Supplement: fish oil|Other: placebo|Other: placebo | OHSU Knight Cancer Institute|United States Department of Defense|National Cancer Institute (NCI) | 2005-07-01 | 2015-02-17 | |
NCT00917735 | Breast Cancer | Drug: Green tea extract supplement|Other: Placebo | University of Minnesota - Clinical and Translational Science Institute|National Cancer Institute (NCI) | Phase 2 | 2009-07-01 | 2016-01-25 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们